Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell
      Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
    • Subject Terms:
    • Abstract:
      Skin hyperpigmentation after sclerotherapy with polidocanol-containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol-containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches and truncal varices with polidocanol-containing sclerosants was performed. Reported incidence rates, follow-up periods and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for polidocanol 0.5% (liquid and foam) and between 13% and 73% for polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for polidocanol 1% (liquid and foam), from 16% to 17% for polidocanol 2% (foam) and from 7.4% to 32.5% for polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam polidocanol 1%-3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol-related sclerotherapy are poor and should be improved by higher-quality research.
      (© 2022 European Academy of Dermatology and Venereology.)
    • References:
      Goldman MP, Weiss RA. Treatment of varicose and telangiectatic leg veins. 6th ed. Edinburgh, UK: Elsevier; 2017.
      Willenberg T, Bossart S. Treatment of varicose veins with minimal invasive strategies. Med Res Arch. 2021;9(5):1-11. https://doi.org/10.18103/mra.v9i5.2421.
      Ramelet A-A, Perrin M, Kern P, Bounameaux H. Phlebology. 5th ed. Paris: Elsevier; 2008. p. 335-51.
      Schibler F, Borradori L, Ramelet AA. Subcutaneous injection of large volumes of polidocanol. Dermatol Surg. 2019;45(3):476-7.
      Schuller-Petrovic S, Pavlovic MD, Neuhold N, Brunner F, Wölkart G. Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy. J Eur Acad Dermatol Venereol. 2011;25:983-6.
      Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg. 1995;21(1):19-29; quiz 31-2. https://doi.org/10.1111/j.1524-4725.1995.tb00107.x.
      Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. J Am Acad Dermatol. 1989;20(4):643-9. https://doi.org/10.1016/s0190-9622(89)70077-3.
      Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630. https://doi.org/10.1136/bmj.g5630. Erratum in: BMJ. 2015;350:h3326.
      Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg. 2004;30(3):367-72; discussion 372. https://doi.org/10.1111/j.1524-4725.2004.30102.x.
      Gonzalez Ochoa AJ, Carrillo J, Manríquez D, Manrique F, Vazquez AN. Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. J Vasc Surg Venous Lymphat Disord. 2021;9(1):154-62. https://doi.org/10.1016/j.jvsv.2020.06.019.
      Benigni JP, Sadoun S, Thirion V, Sica M, Demagny A, Chahim M. Télangiectasies et varices réticulaires. Traitement par la mousse d'Aetoxysclérol à. 0,25%. Présentation d'une étude pilote. Phlebologie. 1999;52:283-90.
      Albanese V, Cavallaro G. Telangiectasias associated with reticular veins. Sclerotherapy or combined sclerotherapeutic and surgical approach? Minerva Cardioangiol. 2002;50(1):29-37.
      Uncu H. Sclerotherapy: a study comparing polidocanol in foam and liquid form. Phlebology. 2010;25(1):44-9. https://doi.org/10.1258/phleb.2009.008064.
      Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012;38(8):1322-30. https://doi.org/10.1111/j.1524-4725.2012.02422.x.
      Parlar B, Blazek C, Cazzaniga S, Naldi L, Kloetgen HW, Borradori L, et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015;29(3):549-54. https://doi.org/10.1111/jdv.12627.
      Hoss E, Kollipara R, Boen M, Alhaddad M, Goldman MP. Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatol Surg. 2020;46(12):1715-20. https://doi.org/10.1097/DSS.0000000000002709.
      Bayer A, Kuznik N, Langan EA, Recke A, Recke AL, Faerber G, et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):435-43. https://doi.org/10.1016/j.jvsv.2020.05.015.
      Levy JL, Elbahr C, Jouve E, Mordon S. Comparison and sequential study of long pulsed Nd:YAG 1,064 nm laser and sclerotherapy in leg telangiectasias treatment. Lasers Surg Med. 2004;34(3):273-6. https://doi.org/10.1002/lsm.20010.
      Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol. 1990;16(9):800-4. https://doi.org/10.1111/j.1524-4725.1990.tb01563.x.
      McCoy S, Evans A, Spurrier N. Sclerotherapy for leg telangiectasia-a blinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 1999;25(5):381-5; discussion 385-6. https://doi.org/10.1046/j.1524-4725.1999.08263.x.
      Ceulen RP, Bullens-Goessens YI, Pi-Van De Venne SJ, Nelemans PJ, Veraart JC, Sommer A. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatol Surg. 2007;33(3):276-81. https://doi.org/10.1111/j.1524-4725.2007.33062.x.
      Blaise S, Bosson JL, Diamand JM. Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. Eur J Vasc Endovasc Surg. 2010;39(6):779-86. https://doi.org/10.1016/j.ejvs.2010.01.022.
      Li L, Hong XY, Zeng XQ, Luo PL, Yi Q. Technical feasibility and early results of radiologically guided foam sclerotherapy for treatment of varicose veins. Dermatol Surg. 2011;37(7):992-8. https://doi.org/10.1111/j.1524-4725.2011.02021.x.
      Hesse G, Breu FX, Kuschmann A, Hartmann K, Salomon N. Sclerotherapy using air- or CO2-O2-foam. Phlebologie. 2012;41(2):77-88. https://doi.org/10.1055/s-0037-1621805.
      Baeshko A, Shestak N, Korytko S. Results of ultrasound-guided foam sclerotherapy of the great saphenous vein with new parameters of the technique. Vasc Endovascular Surg. 2016;50(8):528-33. https://doi.org/10.1177/1538574416675482.
      Kim PS, Elias S, Gasparis A, Labropoulos N. Results of polidocanol endovenous microfoam in clinical practice. J Vasc Surg Venous Lymphat Disord. 2021;9(1):122-7. https://doi.org/10.1016/j.jvsv.2020.04.015.
      Kurnicki J, Osęka M, Tworus R, Gałązka Z. Ultrasound-guided foam sclerotherapy of great saphenous vein with 2% polidocanol - one-year follow-up results. Wideochir Inne Tech Maloinwazyjne. 2016;11(2):67-75. https://doi.org/10.5114/wiitm.2016.60579.
      Memetoğlu ME, Yılmaz M, Kehlibar T, Günay R, Ketenci B, Demirtaş MM, et al. Ultrasonography-guided foam sclerotherapy in patients with small saphenous vein insufficiency. J Vasc Surg Venous Lymphat Disord. 2020;8(5):799-804. https://doi.org/10.1016/j.jvsv.2020.01.011.
      Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg. 2008;35(2):238-45. https://doi.org/10.1016/j.ejvs.2007.09.006.
      Wu Z, Ma Y. Ultrasound-guided foam sclerotherapy for primary small saphenous vein insufficiency. ANZ J Surg. 2021;91(1-2):158-61. https://doi.org/10.1111/ans.16470.
      Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg. 2002;28(1):52-5. https://doi.org/10.1046/j.1524-4725.2002.01190.x.
      Alòs J, Carreño P, López JA, Estadella B, Serra-Prat M, Marinel-Lo J. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg. 2006;31(1):101-7. https://doi.org/10.1016/j.ejvs.2005.08.018.
      Zhang J, Jing Z, Schliephake DE, Otto J, Malouf GM, Gu YQ. Efficacy and safety of Aethoxysklerol® (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology. 2012 Jun;27(4):184-90. https://doi.org/10.1258/phleb.2011.010094.
      Reich-Schupke S, Weyer K, Altmeyer P, Stücker M. Treatment of varicose tributaries with sclerotherapy with polidocanol 0.5% foam. Vasa. 2010;39(2):169-74. https://doi.org/10.1024/0301-1526/a000023.
      Bossart S, Willenberg T, Ramelet AA, Cazzaniga S, Hunger RE, Seyed Jafari SM. The skin hyperpigmentation index: an objective method of measuring the intensity of hyperpigmentation after sclerotherapy. Phlebology. 2020;35(10):833-5. https://doi.org/10.1177/0268355520941359.
      Bossart S, Cazzaniga S, Willenberg T, Ramelet AA, Heidemeyer K, Uthoff H, et al. Reliability assessment and validation of the skin hyperpigmentation index compared to the physician global assessment score. Dermatology. 2022;238:688-91. https://doi.org/10.1159/000520753.
      Hamel-Desnos C, Allaert FA. Liquid versus foam sclerotherapy. Phlebology. 2009;24(6):240-6. https://doi.org/10.1258/phleb.2009.009047.
      Kern P, Ramelet AA, Wütschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. J Vasc Surg. 2007;45(6):1212-6. https://doi.org/10.1016/j.jvs.2007.02.039.
      Hamel-Desnos CM, Guias BJ, Desnos PR, Mesgard A. Foam sclerotherapy of the saphenous veins: randomised controlled trial with or without compression. Eur J Vasc Endovasc Surg. 2010;39(4):500-7. https://doi.org/10.1016/j.ejvs.2009.11.027.
      Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, Frullini A, Gillet JL, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29(6):338-54. https://doi.org/10.1177/0268355513483280.
      Thibault PK, Wlodarczyk J. Correlation of serum ferritin levels and postsclerotherapy pigmentation. A prospective study. J Dermatol Surg Oncol. 1994;20(10):684-6. https://doi.org/10.1111/j.1524-4725.1994.tb00453.x.
      Gutierrez R. How to prevent complications and side effects from sclerotherapy of the lower limb veins. Phlebolymphology. 2018;25(2):137-53.
      Izzo M, Mariani F, Binaghi F, Amitrano M. Postsclerotherapy hyperpigmentation: incidence, clinical features and therapy. In: Negus D, Jantet G, Coleridge-Smith PD, editors. Phlebology ’95. London: Springer; 1995. p. 550-2. https://doi.org/10.1007/978-1-4471-3095-6_255.
      Kern P. Les complications de la micro-sclérothérapie des télangiectasies. Phlebologie. 2010;63(1):31-6.
      Bogachev VY, Boldin BV, Turkin PY. Administration of micronized purified flavonoid fraction during sclerotherapy of reticular veins and telangiectasias: results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1. Adv Ther. 2018;35(7):1001-8. https://doi.org/10.1007/s12325-018-0731-z.
      Scultetus AH, Villavicencio JL, Kao TC, Gillespie DL, Ketron GD, Iafrati MD, et al. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg. 2003;38(5):896-903. https://doi.org/10.1016/s0741-5214(03)00920-0.
      Triba H, Vin F. Les pigmentations résiduelles post-sclérothérapie. Phlebologie. 2011;64(1):41-7.
      Heidemeyer K, Feldmeyer L, Raeber I, Dietrich N, Cazzaniga S, Yawalkar N, et al. Successful treatment of iatrogenic cutaneous siderosis with pigment lasers: a retrospective study in 15 consecutive patients. Acta Derm Venereol. 2020;100(10):adv00148. https://doi.org/10.2340/00015555-3503.
    • Accession Number:
      0AWH8BFG9A (Polidocanol)
      0 (Sclerosing Solutions)
      3055-99-0 (dodecylnonaoxyethylene glycol monoether)
      3WJQ0SDW1A (Polyethylene Glycols)
    • Publication Date:
      Date Created: 20221005 Date Completed: 20230117 Latest Revision: 20230117
    • Publication Date:
      20240829
    • Accession Number:
      10.1111/jdv.18639
    • Accession Number:
      36196455